Therefore, based on the specific immune signature of the TNBC tumor environment, where the immune checkpoint molecules CD47 and PD-L1 are over-expressed, we present here three novel dual-targeting fusion proteins for the treatment of TNBC. This evidence concerns the gene CD47 and neoplasm.